Zimmer Biomet’s rating and oultook affirmed at Moody’s as Paragon 28 deal enhances growth and diversifies business

Published 29/01/2025, 16:08
© Reuters.

Investing.com -- Zimmer Biomet Holdings (NYSE:ZBH), Inc. has announced Tuesday evening plans to acquire Paragon 28, Inc. (Paragon 28), a move that Moody’s (NYSE:MCO) Ratings (Moody’s) predicts will increase leverage, support future growth, and diversify the company’s business. The ratings agency stated that this development will not affect Zimmer’s ratings, including its Baa2 senior unsecured notes ratings. Zimmer’s outlook remains stable.

The transaction, valued at an equity value of about $1.1 billion and an enterprise value of roughly $1.2 billion, will be financed through a combination of cash on hand and other available debt funding sources. Moody’s estimates that leverage will rise from approximately 2.9x to 3.4x pro forma Last Twelve Months (LTM) as of September 30, 2024. However, this figure is expected to fall below 3.25x by the end of 2025, as Zimmer reaps the benefits of synergies and continues to expand due to its recent product launches.

The acquisition of Paragon 28 will allow Zimmer to deepen its footprint in the foot and ankle orthopedic segment. Paragon 28 boasts a wide range of surgical offerings and product systems that cover all major foot and ankle segments, including fracture and trauma, deformity correction, and joint replacement. This expanded portfolio will enable Zimmer to reduce its dependence on the knee and hip space, which currently accounts for about 41% and 26% of its revenue, respectively, as of September 30, 2024.

The acquisition is still subject to regulatory review and approval from Paragon 28’s shareholders. Zimmer anticipates that the transaction will be completed in the first half of 2025.

Zimmer Biomet Holdings, Inc., headquartered in Warsaw, Indiana, is a leading global company specializing in musculoskeletal healthcare. The company focuses on the development of orthopedic implants for hips and knees, as well as craniomaxillofacial and trauma care. As of LTM September 30, 2024, Zimmer reported revenues of approximately $7.6 billion.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.